Last edition
News about " European Academy of Dermatology and Venereology"
Litfulo Shows Significant Repigmentation Benefits in Phase 3
Pfizer’s two phase 3 trials showed significant improvements in facial and total body repigmentation compared with placebo.
European Academy Of Dermatology And Venereology | 05/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members